Enhertu pushes on the HER2-low door once again
Daiichi and AstraZeneca claim another breast cancer success, and further evidence of the ADC’s activity in very low HER2 expression.
Deal analysis part two – the good
A look at big oncology deals since 2016 finds outright success stories hard to come by.
